About
Our vision
Scientists have discovered a fundamental aspect of cell biology, resulting in the creation of an entirely new field of research focused on ‘exosomes’.
Technically exosomes are but one category in the field known in a broader sense as extracellular vesicles. Now, exploring and understanding the underlying biology of exosomes is opening up countless opportunities to co-opt the newly described biological processes for the purpose of engineering novel, purposefully-designed therapeutic entities.
Exocure Sweden AB is seeking to:
- Deploy the novel science underlying exosomes to design and test novel therapeutic candidates for serious unmet medical needs
- Develop know-how, create proprietary information, and submit patents to capture the IP therein, and ultimately,
- Further discover and characterize the biology underlying exosome processes.
Thus, ExocureTM is a platform company, developing the technology and methods to manipulate and manufacture vesicles, and then translate the exosome platform into specific therapeutics to be pursued for specific disease indications. In this way, Exocure will ensure successful outcomes for patients and clinicians to develop advanced medicines to achieve progress in otherwise incurable diseases.
We thank you for your interest in this innovative biotechnology opportunity.
Board
Mats G Persson
Mats Persson has over 30 years experience in global management and business development in pharma and medtech, latelly as Senior Vice President Business Development at SHL Group until 2019, when the company was partly sold to investors. SHL is a Swiss world-leading solutions provider in the design, development, and manufacturing of advanced delivery devices. <em>Other current assignments:</em> Chairman of the Board of Nexos Biosciences AB and Panexo Biosciences AB, and Board member of Bicurion Therapeutics AB, which are subsidiaries of Exocure Sweden AB; Board member of Synartro AB; CEO of Onsala Adventures AB and P&T Invest AB.
Jan Lötvall
Jan Lötvall is an internationally acclaimed pioneer of exosome research. In 2007 he established a world-leading research facility at University of Gothenburg focusing on exosome research, which he continues to lead. He is known for his ground-breaking research in the field including a seminal paper in Nature Cell Biology 2007, Lipid Prize Winner for "the discovery of exosomal shuttle of RNA between cells" 2023, Chief Scientist at Codiak BioSciences 2016-2018, ISEV Special Achievement Award for Exosome Science 2013, First President of the International Society for Extracellular Vesicles 2011-2016 (www.isev.org). <em>Other assignments:</em> Board member of Bicurion Therapeutics AB, Nexos Biosciences AB and Panexo Biosciences AB, which are subsidiaries of Exocure Sweden AB.
Richard Bergström
Richard Bergström is Vice President European Affairs IQVIA, and was Sweden’s vaccine coordinator for COVID19. He was previously Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and served for nine years as the Director General of LIF, the Swedish Association of the Pharmaceutical Industry, following positions in Switzerland in regulatory affairs at Roche and Novartis. <em>Other assignments:</em> Board member of Bicurion Therapeutics AB, Nexos Biosciences AB and Panexo Biosciences AB, which are subsidiaries of Exocure Sweden AB; Board member of European Health Forum Gastein and Institute of Health Economics; CEO for Bergström Consulting GmbH.
Helena Lundquist
Helena Lundquist is a member of the business development team at GU Ventures. She has a long pharma background and is an expert in finance, business and company development. Her experience includes board and management work, business development and venture capital. She has an interest in early-stage startups as well as creating partnerships with the academia, healthcare and industry. <em>Other assignments:</em> Board member of Nexos Biosciences AB, which is a subsidiary of Exocure AB; Chairman of the Board for AMiLion Technology AB; Board member of Simplexia AB, Videm AB and CerInvent AB; alternate board member in Navari Surgical AB, Implexion Pharma AB and SiMSen Diagnostics AB.
Catharina Gustafsson Wallich
Catharina Gustafsson Wallich has a background as senior business executive at AstraZeneca, Amgen, Shire etc in multiple disease areas. She has been a member of several International Corporate Executive teams and as the leader of International Commercial organisations and multidisciplinary, cross-functional teams. A key executive responsibility has been to provide the strategic commercial input to evaluations of R&D projects, prioritization of pipeline, business development and product development decisions. <em>Other ongoing assignments:</em> Board member of Bicurion Therapeutics AB, Nexos Biosciences AB and Panexo Biosciences AB, which are subsidiaries of Exocure Sweden AB; Board member of IRLAB and Mevia AB; Deputy board member at PCW Consultants AB.
Klementina Österberg
Klementina Österberg is CEO of GU Ventures, where she manages a broad team of business experts, project managers and financial staff supporting startups in their portfolio, like Exocure. She has 25+ years within organizational and business development as well as investments. Her expertise includes also operational and expert functions including recruitments, communications and option programs. She holds board and chairperson positions in portfolio companies and she has worked with creating partnerships with the academia, healthcare and industry. She has been appointed Finance Profile of the Year in 2019 and Female Leader of the Year in 2016 in the region. <em>Other assignments:</em> Alternate board member of Bicurion Therapeutics AB, Nexos Biosciences AB and Panexo Biosciences AB, which are subsidiaries of Exocure Sweden AB; and in other companies in the GU Ventures portfolio of which she is chair person of the board in three investment vehicles, Destination Invest i Göteborg, GOKAP Invest and Vasa Angels.
Management
Søren Melsing
Søren Melsing is an experienced drug developer with additional experience in commercialization. His expertise ranges from R&D, project management, sales management, marketing, and product launch. He has been engaged in all elements of the pharmaceutical commercial work including market access, medical affairs, commercial strategy, and sales execution. <em>Other assignments:</em> CEO for Bicurion Therapeutics AB, Nexos Biosciences AB and Panexo Biosciences AB, which are subsidiaries of Exocure Sweden AB; Board member of Spermosens AB and STENOCARE A/S, CEO for SML Holding ApS.
Magnus Käll
Magnus Käll has worked 25 years in various financial roles in amongst others Hellberg Safety AB, APV Steridose, Volvo AB, Cochlear BAS AB and Cochlear Nordic AB, and is now employed at GU Ventures AB, an investor in Exocure Sweden AB. <em>Other assignments:</em> CFO at Bicurion Therapeutics AB, Nexos Biosciences AB and Panexo Biosciences AB, which are subsidiaries of Exocure Sweden AB; and CFO at Simplexia AB, Brain Biomarker Solutions Gothenburg AB, STB INN AB, Videm AB, Identinano AB, and Destination Invest i Göteborg AB. CEO of Zequre Europe AB.
Kyong-su Park
Kyong-su Park has studied exosomes since 2007, and is a senior researcher at Krefting Research Centre in University of Gothenburg, Sweden. He has a Ph.D. in the Pohang University of Science and Technology (POSTECH), South Korea, where he studied the field of exosomes derived from both eukaryotic and bacterial cells. He has worked at Hanmi Pharmaceutical Co., Ltd., South Korea, where he researched about the development of new drug in diabetes and obesity field. His focus is on the therapeutic exosomes targeting multiple inflammatory diseases, sepsis and cancer immunotherapy, as well as development of diagnostic tools against infectious diseases and tumors. <em>Other assignments:</em> Board member Nexos Biosciences AB which is a subsidiary of Exocure AB.
Scientific Advisor
Roger Olofsson Bagge
Roger Olofsson Bagge is Professor in Clinical Surgery, and is the Head of Breast and Melanoma Surgery at Sahlgrenska University Hospital. He has a vast experience in translational exosome research in the context of cancers. Roger is the scientific advisor for Bicurion Therapeutics AB which is a subsidiary of Exocure AB.